Results 51 to 60 of about 11,837 (160)

Necrotising Soft Tissue Infections: A Single Center's Case Series

International Wound Journal, Volume 23, Issue 3, March 2026.
ABSTRACT Necrotising soft tissue infection (NSTI) is a progressive disease with a time‐dependent prognosis; if not promptly treated, it can lead to significant morbidity as well as mortality. Early and aggressive surgical treatment is mandatory for appropriate management. This study reports the diagnostic and therapeutic pathway, surgical treatment and
Francesca Toia, Andrea Pio Cascino, Mara Franza, Marco Romeo, Antonino Speciale, Adriana Cordova, Massimiliano Tripoli   +6 more
wiley   +1 more source

Evolution of ceftazidime–avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae

mSystems
Klebsiella pneumoniae carbapenemase (KPC) variants can contribute to resistance to ceftazidime–avibactam (CZA) in Klebsiella pneumoniae (KP). However, two-copy KPC variant-mediated resistance to CZA has rarely been reported to date.
Xiaofan Zhang, Yinrong Xie, Ying Zhang, Tailong Lei, Longjie Zhou, Jiayao Yao, Lin Liu, Haiyang Liu, Jintao He, Yunsong Yu, Yuexing Tu, Xi Li   +11 more
semanticscholar   +1 more source

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +1 more source

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae

Emerging Microbes and Infections
Ceftazidime-avibactam resistance attributable to the blaKPC-2 gene mutation is increasingly documented in clinical settings. In this study, we characterized the mechanisms leading to the development of ceftazidime-avibactam resistance in ST11-K47 ...
Qingyu Shi, S. Shen, Chengkang Tang, Li Ding, Yan Guo, Yang Yang, Shiann-Ching Wu, Renru Han, D. Yin, F. Hu   +9 more
semanticscholar   +1 more source

Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
ABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Jingjing Wang, Jinjie He, Jufang Wu, Jing Zhang, Ying Ma, Xiaoqing Ren, Hua Wei, Chunye Zhang, Hua Zhu, Susan R. Raber, Shuangchen Cong   +10 more
wiley   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

Frontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang, Yun Han, Yinshan Wu, Feng Guo, Zhenwei Yu   +4 more
doaj   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

International Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source

Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.

International Journal of Antimicrobial Agents
Enterobacterales with carbapenemase-independent resistance to carbapenems are sometimes being selected during therapy and, on rare occasions, cause outbreaks.
S. Mushtaq, A. Vickers, N. Woodford, David M Livermore   +3 more
semanticscholar   +1 more source

Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem‐Resistant Klebsiella pneumoniae (CRKP) Infections

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang, Ze Fang, Bo Fang, Hailing Zeng, Jiaojiao Xu, Muhammad Abu Bakr Shabbir   +5 more
wiley   +1 more source